Search clinical trials for: CKD-519 200 mg

Total 1762 results

Chong Kun Dang Pharmaceutical

Completed

Study to Evaluate the Drug Interaction Between CKD-519 and Rosuvastatin in Healthy Male Subjects

Dyslipidemias

Korea, Republic of
Chong Kun Dang Pharmaceutical

Completed

To Assess the Safety, Efficacy and Tolerability of CKD-519, Administered With HMG-CoA Reductase Inhibitors

Dyslipidemias

Australia
University of Calgary

Not yet recruiting

Cannabis for the Prophylactic Treatment of Migraine

Chronic Migraine
Impax Laboratories, LLC

Completed

Pharmacokinetics and Pharmacodynamics of IPX054 in Subjects With Parkinson's Disease

Idiopathic Parkinson's Disease

United States
Chong Kun Dang Pharmaceutical

Completed

Study to Assess PK/PD Character, Safety/Tolerability of CKD-519 New Formulation in Healthy Male Subject.

Dyslipidemia

Korea, Republic of
Chong Kun Dang Pharmaceutical

Completed

Study to Investigate the Effects of Food on the Pharmacokinetics/Pharmacodynamics of CKD-519

Healthy Volunteers

Korea, Republic of
Centre hospitalier de l'Université de Montréal...

Completed

A Study of Ingested Cannabidiol in Healthy Occasional Cannabis Users

Cannabis

Canada
Chong Kun Dang Pharmaceutical

Completed

Study to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CKD-519

Dyslipidemia

Korea, Republic of
Chong Kun Dang Pharmaceutical

Completed

Study to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CKD-519

Dyslipidemia

Korea, Republic of
Chong Kun Dang Pharmaceutical

Completed

Study to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CKD-519 (CKD-519 FIH)

Dyslipidemia

Korea, Republic of
Ilkos Therapeutic Inc.

Completed

Dose-response Relationship Study of S42909 on Leg Ulcer Healing

Venous Leg Ulcer

Spain, Hungary, Canada, United States, Brazil, Argentina, Austria, Czechia, Italy, Poland, Slovakia
Guangdong Zhongsheng Pharmaceutical Co., Ltd.

Completed

The Safety, Tolerability and Pharmacokinetic Study of ZSP1273 in Healthy Volunteers.

Influenza

China
Yuhan Corporation

Completed

AME Study of [14C]-YH4808 in Healthy Male Subjects

Healthy

United States
Chong Kun Dang Pharmaceutical

Unknown

Clinical Trial to Investigate the Pharmacokinetics and Safety of CKD-393

T2DM (Type 2 Diabetes Mellitus)

Korea, Republic of
CVI Pharmaceuticals

Unknown

Safety and Efficacy of CVI-LM001 in Patients With Hypercholesterolemia

Hyperlipidemia

China
Zhejiang Hisun Pharmaceutical Co. Ltd.

Unknown

Trial of Ginsenoside Compound K (GCK) Tablet in Patients With Rheumatoid Arthritis

Early Rheumatoid Arthritis

China
Chong Kun Dang Pharmaceutical

Completed

Evaluation of the Safety and Tolerability of CKD-510 in Healthy Subjects

Healthy Volunteers

France
Valenta Pharm JSC

Completed

A Study to Evaluate the Safety, Tolerability and Efficacy of XC221 in Patients With Uncomplicated Influenza or Other Acute Viral Upper Respiratory Infections

Influenza | Viral Respiratory Infection | Acute Viral Upper Respiratory Infections

Russian Federation
PHARMENTERPRISES LLC

Completed

Study to Assess Efficacy and Safety of XC221 in the Treatment of Influenza and Other Acute Respiratory Viral Infections

Influenza | Acute Respiratory Viral Infections

Russian Federation
Forest Laboratories

Completed

Effects of Itopride on Gastric Motor and Sensory Functions in Healthy Volunteers

Healthy

United States
Chong Kun Dang Pharmaceutical

Completed

A Study to Evaluate the Relative Bioavailability of Formulations of CKD-510 and to Assess the Effect of Food on the CKD-510 Tablet Formulation in Healthy Subjects

Healthy Volunteers

United States
Bial - Portela C S.A.

Completed

Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 3-202 and Metabolites

Parkinson's Disease

Switzerland
Chong Kun Dang Pharmaceutical

Completed

Safety Study of Increasing Doses of CKD-516 in Patients With Advanced Solid Cancers

Unspecified Adult Solid Tumor, Protocol Specific

Korea, Republic of
Chong Kun Dang Pharmaceutical
Seoul National University Hospital

Completed

Safety Study of Increasing Doses of CKD-516 in Patients With Advanced Solid Cancers

Unspecified Adult Solid Tumor, Protocol Specific

Korea, Republic of
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

Tolerability and Pharmacokinetics of CSPCHA115 Capsules in Chinese Healthy Volunteers

Asthma; Allergic Rhinitis

China
NP Therapeutics

Completed

Study to Assess Safety, Tolerability and Pharmacokinetics of XC7 (Which is Planned Use in the Treatment of COVID-19) in Healthy Volunteers

Covid19 | Healthy Volunteers

Russian Federation
GlaxoSmithKline

Completed

A Dose Ranging Study to Evaluate the Safety and Efficacy of GSK2586184 in Patients With Chronic Plaque Psoriasis

Psoriasis

Germany, United Kingdom
Eisai Co., Ltd.

Completed

A Double-Blind Study of E5555 in Japanese Subjects With Coronary Artery Disease

Coronary Artery Disease

Japan
Chong Kun Dang Pharmaceutical
Asan Medical Center

Unknown

A Phase 1/2a Study to Assess the Safety and Efficacy of CKD-516 Tab. in Combination With Irinotecan Inj.

Colorectal Cancer

Korea, Republic of
Galapagos NV

Completed

Multiple Ascending Dose Study of GLPG0634 in Japanese and Caucasian Healthy Subjects

Healthy

United Kingdom
Impax Laboratories, LLC

Completed

Comparison of IPX054 and Immediate-Release Carbidopa-Levodopa in Patients With Parkinson's Disease

Parkinson's Disease

United States
Zhejiang Genfleet Therapeutics Co., Ltd.

Completed

A Phase I Study of GFH312 in Healthy Chinese Subjects

Healthy Volunteer

China
Galapagos NV

Completed

A Study to Evaluate Multiple Doses of GLPG2222 in Adult Subjects With Cystic Fibrosis

Cystic Fibrosis

Spain, United Kingdom, United States, Netherlands, Belgium, Serbia
GlaxoSmithKline

Terminated

An Adaptive Phase II Study to Evaluate the Efficacy, Pharmacodynamics, Safety and Tolerability of GSK2586184

Systemic Lupus Erythematosus

Estonia, Germany, South Africa, Peru, Sweden, France, Korea, Republic of, Hong Kong, Spain, Romania, Czechia, Argentina, Chile, Hungary, Greece, Poland
McGill University Health Centre/Research Institute...
Centre de Recherche du Centre Hospitalier de l'Université de Montréal; CIHR... and other collaborators

Terminated

Cannabinoids in PLWHIV on Effective ART

HIV Infections

Canada
VIVUS LLC

Completed

Research Evaluating a PDE5 Inhibitor for Erectile Dysfunction

Erectile Dysfunction

United States
New York State Psychiatric Institute
National Institute on Drug Abuse (NIDA)

Withdrawn

NT-814: Evaluation of Its Ability to Alter the Abuse Liability of Oxycodone in an Exploratory Clinical Study (NT-814)

Opioid Use Disorder

United States
Chong Kun Dang Pharmaceutical

Completed

Study to Investigate the Effect of Food on the Pharmacokinetics/Pharmacodynamics and Safety of CKD-519(CKD-519 FDI)

Dyslipidemia

Korea, Republic of
GlaxoSmithKline

Completed

Single Dose Escalation First Time in Human PK Study

Infections, Bacterial

Australia
National OncoVenture
Chong Kun Dang Pharmaceutical

Unknown

NOV120401 (CKD-516 Tablet) for Advanced Solid Tumors

Advanced Refractory Solid Tumors

Korea, Republic of
Chong Kun Dang Pharmaceutical

Completed

Study to Investigate the Influence of CKD-519 on 24-h Ambulatory Blood Pressure in Healthy Adult Volunteers

Healthy Volunteers

Korea, Republic of
Procter and Gamble

Completed

Efficacy and Safety of PG-530742 in the Treatment of Mild to Moderate Knee Osteoarthritis

Osteoarthritis, Knee

Hungary, United Kingdom
Transposon Therapeutics, Inc.

Active, not recruiting

A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP)

Progressive Supranuclear Palsy

United States
Boehringer Ingelheim

Completed

Relative Bioavailability of Different Formulations of BI 671800 in Healthy Male and Female Volunteers

Healthy
OrthoTrophix, Inc

Completed

A Study Evaluating the Safety and Efficacy of a Second Course of TPX-100 in Subjects Who Previously Received TPX-100 for Patellar Osteoarthritis Involving Both Knees

Knee Osteoarthritis
PHARMENTERPRISES LLC

Completed

Double-blind, Randomized, Placebo-controlled Study of the Safety, Tolerability and Pharmacokinetics of Ascending Doses of XC243 After Single and Multiple Oral Administration in Healthy Volunteers.

Healthy Volunteers

Russian Federation
Yungjin Pharm. Co., Ltd.

Completed

Safety, Tolerability and Pharmacokinetic Study of KL1333 in Healthy Male Volunteers

MELAS Syndrome | Mitochondrial Respiratory Chain Deficiencies

Korea, Republic of
University of California, San Francisco
San Francisco VA Health Care System

Completed

Pilot Human Lab Study of Lacosamide in Alcohol Use Disorder (AUD) (ACGT)

Alcohol Use Disorder

United States
Basilea Pharmaceutica

Completed

Derazantinib and Atezolizumab in Patients With Urothelial Cancer (FIDES-02)

Urothelial Carcinoma

United Kingdom, Korea, Republic of, Italy, Canada, France, Spain, Germany, United States, Hungary, Australia, Poland, Switzerland, Czechia, Austria
Tae Won Kim

Terminated

The Efficacy and Safety of CKD516 Combined With Durvalumab in Patient Refractory Solid Tumors

Colorectal Cancer | Solid Tumor

Korea, Republic of

Search clinical trials for: CKD-519 200 mg

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Rwanda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations